| Literature DB >> 25104974 |
Abstract
BACKGROUND: Onychomycosis is a common nail pathology which has proven to be a treatment challenge to healthcare professionals. Antifungal drugs have been the mainstay of therapy for many years. Recently, laser technologies have been introduced as a treatment for onychomycosis avoiding the disadvantages of systemic and topical drug therapies, offering a rapid treatment for an often persistent nail condition. The purpose of this study was to review published evidence regarding the effectiveness of laser technologies in the treatment of onychomycosis.Entities:
Keywords: Fungal; Laser; Nail; Nd:YAG; Onychomycosis
Year: 2014 PMID: 25104974 PMCID: PMC4124774 DOI: 10.1186/1757-1146-7-34
Source DB: PubMed Journal: J Foot Ankle Res ISSN: 1757-1146 Impact factor: 2.303
Figure 1Flow Diagram of search strategy (conducted June 2014).
Summary of studies included in the review
| Carney et al. [ | Case Series | 10 (18) | 1064 nm Nd:YAG (short Pulse). 1 treatment. | Culture | 24 weeks | Decrease in area of nail visually affected measured with the Onychomycosis Severity Index (OSI) and negative cultures. |
| Hees et al. [ | Comparative study | 10 (20) | 1064 nm (long v. short pulse) on each hallux 2 treatments over 4 weeks (side by side comparison). | Histology | 36 weeks | Decrease in area of nail visually affected measured with the Onychomycosis Severity Index (OSI). Negative histology & cultures. |
| Hochman [ | Case Series | 8 (12) (1)* | 1064 nm (short pulse). 2 or 3 treatments, 3 weeks apart. | Culture or PAS | 24 weeks | Negative fungal cultures. |
| Hollmig et al. [ | RCT | 27 (125) | 1064 Nd:YAG. 2 Treatments 2 weeks apart versus control. | Culture or PAS | 52 weeks | Negative cultures and measured clearance at 3 months for all subjects, and repeated clearance measurement at 12 months for those treated with laser. |
| Kalokasidis et al. [ | Case Series | 131 (unknown) | 1064 nm/532 Q switched Nd:YAG. 2 treatments, 30 days apart. | Microscopy & Culture | 12 weeks | Decrease in area of nail visually affected measured with the Onychomycosis Severity Index (OSI) and negative cultures. |
| Kimura et al. [ | Case Series | 13 (37) | Nd:YAG 1064 nm (long Pulse) 2–3 treatments, 4 weeks apart. | Microscopy | Improvements in nail turbidity score and, negative culture if nail was 100% improved in turbidity score. | |
| Landsman et al. [ | RCT | 36 (37) | 870 nm/930 nm laser or sham control device. 4 treatments over 60 days. | Culture or PAS | 24 weeks | Decrease in affected nail area (clearance) and negative culture or PAS stain. |
| Lim et al. [ | Case Series | 24 (unknown) | CO2 laser. 3 treatments at 4 weeks plus topical treatment. | Microscopy | 24 weeks | Decrease in affected nail surface area and negative microscopy. |
| Moon et al. [ | Case Series | 13 (43) (12)* | 1064 nm Nd:YAG (long pulse). 5 treatments at 4 week intervals. | Microscopy & Culture | 24 weeks | Decrease in affected nail surface area and negative microscopy. |
| Noguichi et al. [ | Case Series | 12 (12) | 1064 nm Nd:YAG (long Pulse) 3 treatments at 4 week intervals. | Microscopy or PCR or culture | 24 weeks | Decrease in nail surface area affected and negative microscopy. |
| Waibel et al. [ | Comparative study | 21 (21) | 1064 nm ND:YAG v. 1319 nm v. Broadband light. 4 treatments at one week apart. | Culture & PAS | 24 weeks | Negative fungal culture. |
| Zhang et al. [ | Comparative study | 33 (154) (18)* | 1064 nm Nd:YAG (long pulse) Either 4 | Microscopy & Culture | 24 weeks | Negative culture and measured decrease in affected nail surface area. |
Appraisal of study validity using the AOTA Evidence Based Project Scale[23]
| Carney et al. [ | IV | C | 2 | 20% attrition | b | Only DLSO mycosis of the hallux included |
| Unblinded assessment | ||||||
| Hees et al. [ | III-3 | C | 1 | | b | Only T Rubrum mycosis included |
| Hochman [ | IV | C | 2 | Antifungal cream used post intervention. | b | Type of onychomycosis treated not classified |
| Variable follow up periods | ||||||
| Hollmig et al. [ | II | B | 2 | Blinding procedures not stated | b | Type of onychomycosis treated not classified |
| 18% attrition | ||||||
| Kalokasidis et al. [ | IV | A | 3 | Short follow up period OSI results not fully reported | b | Mainly mild/DLSO mycosis treated |
| No control group | ||||||
| Kimura et al. [ | III-3 | A | 3 | Variable no. of treatments (1–3) | b | Mainly DLSO mycosis treated |
| Turbidity scoring not validated | ||||||
| Landsman et al. [ | II | B | 2 | Smaller control than treatment group | b | Majority cases mild to moderate mycosis |
| Industry sponsorship/authorship | ||||||
| Lim et al. [ | IV | B | 2 | Blinding procedures for nail grading not clear. | b | Majority cases mild to moderate mycosis |
| Not stated how many finger v. toe nails included | ||||||
| Moon et al. [ | IV | C | 2 | Limited details on nail scoring system validation | b | Mainly (DLSO) included |
| Noguichi et al. [ | IV | C | 2 | Limited detail on independence of nail score assessment | b | Severe nail disease or thick nails excluded - only mild/DLSO cases included |
| Waibel et al. [ | III-3 | B | 2 | No control/placebo group | b | Types of mycosis included not reported |
| Limited detail on how nail clearance assessed and reported | ||||||
| Zhang et al. [ | III-3 | B | 3 | No control/placebo group | b | Types of mycosis included not reported |
| Limited detail on how nail clearance assessed |
**NHMRC Hierarchy of Evidence adapted from [22].